Currently Viewing:
The Clinical and Reimbursement Landscape of Immuno-Oncology

Integrating Immunotherapy in Lung Cancer

Andrew L. Pecora, MD, offers insight regarding the treatment of non—small cell lung cancer and the timing of immunotherapy initiation.


Immunotherapy has demonstrated efficacy in lung cancer, for which there are drugs approved as second-line therapies, states Andrew L. Pecora, MD. First-line doublet chemotherapy is given for metastatic non–small cell lung cancer (NSCLC). If the patient has an ALK or EGFR mutation, treatment would include a targeted therapy.
 
Chemotherapy is never curative in metastatic NSCLC, says Pecora. An anti-PD-1 agent can be given once chemotherapy fails, although there is some debate regarding whether to give immuno-oncology agents up front in order to stimulate the immune system earlier in the disease process.
 
When nivolumab is added to ipilimumab, there is an increase in the rate of response, adds Pecora. The combination has the potential to improve survival. One issue with combining a PD-1 inhibitor with an anti-CTLA4 agent is toxicity. Once the immune system is stimulated, it can produce adverse effects that must be addressed quickly, says Pecora. Using these agents at a lower dose and/or altering the sequencing could, in theory, help reduce these effects.
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!